As more information becomes available pertaining to the Coronavirus pandemic and the association with certain pre-existing medical conditions, health experts are growing concerned about one group in particular; those individuals with Type-2 diabetes.

There is now a solid base of scientific evidence which shows that there is an increased risk of developing complications from COVID-19 among those individuals who have diabetes.Information published on the website of the American Diabetes Association provides as assessment of how COVID-19 impacts people with diabetes.

It seems that the Coronavirus pandemic could have serious health implications for those who are at risk from the global diabetes epidemic. The major difference between the two is that the Coronavirus pandemic has been around for less than a year, whereas the diabetes epidemic has been around for decades.

The two now appear to be on a collision course, with dire health consequences for those individuals who unfortunately find themselves dealing with both COVID-19 and Type-2 diabetes at the same time. 

Fortunately, our knowledge of the Coronavirus has expanded, as scientists learn more about the traits and characteristics of this deadly pathogen.  

For years, we have known that obesity is a major contributing factor to the risk of developing Type-2 diabetes. As the number of people who are technically defined as “obese”, i.e., having a Body Mass Index (BMI) above 30 has grown, so has the number of individuals who have developed diabetes.

This trend is alarming. 

To make matters worse, according to statistics compiled by the CDC, there are 34.2 million people in the U.S. who have been clinically diagnosed with diabetes.

More importantly, according to the CDC, there are another 88 million, or 1-in-3 adults so, who have pre-diabetes. Even more shocking is the fact that as many as 8 in 10 adults don’t even realize that they are pre-diabetic.

Data collected by the global scientific community and world health officials, and published by Statista, have discovered that over 40% of U.S. adults are susceptible to experiencing a severe reaction to COVID-19 as a result of pre-existing conditions.

The two largest groups considered “at risk” are those who suffer from obesity and Diabetes.

The increase in obesity rates over the years are clearly shown by this PowerPoint presentation which appears on the CDC website.  

The Center For Disease Control national obesity rate maps, however, do not tell the entire story. Looking much deeper into the statistics, we find that the obesity rates among Non-Hispanic Black Adults is much higher than the obesity rates among the general population.

The increased risk among this sub-group has been clearly shown by a group called The Covid Tracking Project.

The COVID Racial Data Tracker is a collaboration between the COVID Tracking Project and the Boston University Center for Antiracist Research.

The data on the Covid Tracking Project website shows that minorities are being hit much harder by COVID-19 than non-minority groups.

In fact, nationwide black people are dying at 2.5 times the rate of white people.

Other minority groups, such as American Indian, Alaska Native, Hispanics and Latinos are also dying at a much higher rate than whites.

According to The Journal of Clinical Endocrinology & Metabolism, it is many of these same minority groups that also have higher incidents of both obesity along with developing a pre-disposition to diabetes.

Despite these startling statistics, among minority groups, it remains a fact that the Coronavirus impacts everyone no matter what their racial background. 

White people, who suffer from obesity along with Type-2 diabetes have the same overall increased risks as do other patients who have contracted COVID-19. 

There has been an awareness building, among the public, regarding the combined risks that obesity, diabetes and COCVID-19 pose, and why a confluence of these factors can be devastating to a person’s health condition.

Articles in publications such as Obesity Action Community, the American Society for Metabolic and Bariatric Surgery and Diabetes Self-Management all point out the dangerous and sometimes deadly link between obesity and diabetes.

Now, what has become even more concerning among doctors and scientists, is the apparent link between obesity, diabetes and the susceptibility to increased and more severe COVID-19 complications and health risks. 

As was pointed out earlier in this article, the COVID-19 pandemic is a recent occurrence, but the Diabetes epidemic has been growing globally for years.

Many of the large drug store chains are beginning to realize that consumer spending on diabetes-related therapeutics is likely to increase in the coming years, as the global epidemic of diabetes continues to grow.

In fact, many of them are expanding their in-store offering of newly-developed products, designed to help people suffering from diabetes better manage their condition.  Many of them are managing this transition at a record pace.

Just last year, drug store chain CVS Health announced that they are in the process of making changes to approximately 1,500 of their stores across the country by implementing a strategic vision which they are calling “Health Hubs”.

In its 2018 Annual Report, CVS listed common chronic disease management as the number one strategy in its “core suite of transformation initiatives.” Specifically, CVS wants to focus on the 25% of annual U.S. spend on chronic conditions that is avoidable, and target five conditions—diabetes, cardiovascular disease, hypertension, asthma, and behavioral health—as opportunities for better management.

As part of their plan, they announced their decision to distribute and sell the Glucodown®line of diabetic-friendly tea mixes in their CVS pharmacies nationwide.

Murray Fleming, CEO of Glucose Health, Inc., stated“CVS is embarking on a significant corporate expansion of diabetic care at many of its pharmacies nationwide and we are very pleased GLUCODOWN has been included given the important role nutrition can play in this initiative”.

While it is one thing for a company to expand distribution of its products, it is quite another to see that expansion met with overwhelming consumer demand.

Such has been the case for Glucodown®, a delicious tea mix that has seen sales recently “go through the roof” at Internet retail giant Amazon. In May, the company reported that its sales for the month were up 1,048% from the same month last year in 2019.

In June, the company reported sales for the month had ballooned, up some 1,284% over the same month in 2019.

That’s the good news.

The bad news is that this sudden increase in demand from consumers on Amazon, caused inventory levels of the product to drop substantially. This resulted in a stock-out for a brief period in the month of July.

The company has since scrambled to produce new inventory for Amazon, and the product (depending on the flavor) is either available now or will be shortly, according to Amazon’s website.

While the company attributes these phenomenal sales numbers to increased advertising, among other things, there can be no question that consumers have discovered and embraced the company’s diabetic-friendly products.

Could some of this, in fact, be attributed to the public’s increased awareness of the combined risks that obesity, diabetes and COVID-19 pose?

While no one can say for sure, the recent news regarding month-over-month 1,000% plus sales increases at Amazon, along with a continuing strong relationship with long-time retail partner Walmart, and the newly-formed partnership with national drug store chain giant CVS certainly gives investors a reason to sit up and take notice of what is happening at Glucose Health, Inc. 

About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated four thousand one hundred dollars in consideration for its work with Glucose Health, Inc. through the date this was published. EmergingGrowth.com may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here https://emerginggrowth.com/4582-6827465/.  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.

Add a Comment to this Post

comments